Morgan Stanley Humanigen, Inc Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.13 - $0.2 $157 - $242	-1,211 Reduced 1.92%	62,003 $9,000
Q1 2023 May 15, 2023	SELL	$0.12 - $0.23 $4,694 - $8,997	-39,120 Reduced 38.23%	63,214 $8,000
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.2 $2,985 - $6,633	33,167 Added 47.95%	102,334 $12,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $55,698 - $1.12 Million	-371,324 Reduced 84.3%	69,167 $12,000
Q2 2022 Oct 27, 2022	BUY	$1.76 - $3.33 $139,048 - $263,086	79,005 Added 21.86%	440,491 $779,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.33 $139,048 - $263,086	79,005 Added 21.86%	440,491 $779,000
Q1 2022 Oct 27, 2022	SELL	$1.81 - $3.97 $142,999 - $313,649	-79,005 Reduced 17.94%	361,486 $1.09 Million
Q1 2022 May 13, 2022	SELL	$1.81 - $3.97 $62,122 - $136,258	-34,322 Reduced 8.67%	361,486 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1.12 Million - $2.51 Million	305,712 Added 339.32%	395,808 $1.47 Million
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $534,269 - $1.61 Million	90,096 New	90,096 $533,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.